Affiliation:
1. From the Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC.
Abstract
Abstract
—Superoxide radical (O
2
−
) is increased in the vessel wall of spontaneously hypertensive rats (SHR) where its blockade potentiates endothelium-dependent vasodilation. The purpose of this study was to determine the role of O
2
−
in the hypertension and renal vasoconstriction of SHR and its interaction with nitric oxide (NO). Baseline mean arterial pressure (MAP) and renal vascular resistance were markedly elevated in SHR (n=6) compared with Wistar-Kyoto rats (WKY; n=6) (145±4 versus 118±4 mm Hg,
P
<0.05, and 24±3 versus 17±1 mm Hg · mL
−1
· min
−1
, respectively;
P
<0.05). The stable membrane-permeable superoxide dismutase mimetic 4-hydroxy-2,2,6,6-tetramethyl piperidine-1-oxyl (tempol; 72 μmol/kg IV) normalized MAP (103±9 versus 96±6 mm Hg for SHR and WKY, respectively) and RVR (17±2 versus 15±1 mm Hg · mL
−1
· min
−1
) of SHR. The MAP of SHR was more sensitive and responsive to graded infusions of tempol (0, 1.8, 18, 180, and 1800 μmol · kg
−1
· h
−1
IV) than that of WKY. To determine whether O
2
−
increases MAP by inactivation of NO, its synthesis was blocked in SHR with
N
w
-nitro-
l
-arginine methyl ester (L-NAME, 11 μmol · kg
−1
· min
−1
IV, n=6). Whereas tempol alone significantly reduced MAP by 32% (184±12 to 121±18 mm Hg,
P
<0.05, n=6), L-NAME infusion abolished the MAP response to tempol (187±8 to 186±4 mm Hg, n=5). In contrast, tempol did reduce MAP of SHR (188±7 to 161±7 mm Hg,
P
<0.05) where MAP was elevated by norepinephrine (31 nmol · kg
−1
· min
−1
IV, n=6). Finally, to determine the longer-term effect of O
2
−
, tempol (1.5 mmol · kg
−1
· d
−1
IP) was given for 7 days. Tempol had no effect on MAP in WKY (96±1 to 97±1 mm Hg, n=7) but significantly decreased MAP in SHR (133±2 to 120±3 mm Hg,
P
<0.05, n=7). These data implicate O
2
−
in the hypertension of SHR in vivo. The antihypertensive action of tempol depends on NO synthesis presumably because O
2
−
inactivates NO and thus diminishes its vasodilatory actions.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
453 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献